ATC Group: A10AE Insulins and analogues for injection, long-acting

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10AE in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10A Insulins and analogues
4 A10AE Insulins and analogues for injection, long-acting

Group A10AE contents

Code Title
A10AE01 Insulin (human)
A10AE02 Insulin (beef)
A10AE03 Insulin (pork)
A10AE04 Insulin glargine
A10AE05 Insulin detemir
A10AE06
A10AE07
A10AE30 Combinations
A10AE54 Insulin glargine and lixisenatide
A10AE56 Insulin degludec and liraglutide

Active ingredients in A10AE

Active Ingredient Description
Insulin (human)

The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Insulin (pork)
Insulin degludec

Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Insulin degludec and Liraglutide

Insulin degludec/liraglutide is a combination having complementary mechanisms of action to improve glycaemic control. Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering effect of insulin degludec with a low day-today variability in insulin action. Liraglutide is a Glucagon-Like Peptide-1 (GLP-1) analogue. Liraglutide action is mediated via a specific interaction with GLP-1 receptors and improves glycaemic control by lowering fasting and postprandial blood glucose.

Insulin detemir

Insulin detemir is a soluble, long-acting insulin analogue with a prolonged duration of effect used as a basal insulin.

Insulin glargine

Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. After injection, the acidic solution is neutralised leading to formation of a precipitate from which small amounts of insulin glargine are continuously released.

Insulin glargine and Lixisenatide

Combination of two active substances with complementary mechanisms of action to improve glycaemic control: insulin glargine, a basal insulin analogue (mainly targeting fasting plasma glucose), and lixisenatide, a GLP-1 receptor agonist (mainly targeting postprandial glucose).

Insulin icodec

The primary action of insulin, including insulin icodec, is to regulate glucose metabolism. A slow and steady glucose-lowering effect of insulin icodec is driven by albumin binding as well as reduced insulin receptor binding and clearance. The extended half-life of insulin icodec reflects a depot of insulin icodec in the circulation and in the interstitial compartment, from which insulin icodec is slowly and continuously released and binds specifically to the insulin receptor.

Related product monographs

Title Information Source Document Type  
AWIQLI Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
BASAGLAR Solution for injection Kwikpen / Tempo pen FDA, National Drug Code (US) MPI, US: SPL/PLR
LANTUS Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
LEVEMIR Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SEMGLEE Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
SOLIQUA Solution for injection in pre-filled pen (SoloStar) European Medicines Agency (EU) MPI, EU: SmPC
SULIQUA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
TOUJEO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
TRESIBA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
TRESIBA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
XULTOPHY Solution for injection European Medicines Agency (EU) MPI, EU: SmPC